Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects.
Purpose: Lucerastat is an orally available glucosylceramide synthase inhibitor with a potential to provide substrate reduction therapy for Fabry patients independent of their α-galactosidase A genotype. In humans, lucerastat is mainly eliminated as unchanged parent compound through renal excretion b...
| Published in: | European Journal of Clinical Pharmacology Vol. 76; no. 3; pp. 431 - 438 |
|---|---|
| Main Authors: | , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Springer Nature
Mar2020
|
| Online Access: | View this record in EBSCOhost |